Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Maravai LifeSciences Holdings, Inc. - Class A common stock (NQ:MRVI)

2.880 +0.070 (+2.49%)
Streaming Delayed Price Updated: 2:14 PM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 426,835
Open 2.830
Bid (Size) 2.870 (9)
Ask (Size) 2.880 (9)
Prev. Close 2.810
Today's Range 2.800 - 2.910
52wk Range 1.665 - 9.500
Shares Outstanding 112,280,375
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MARAVAI INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Maravai LifeSciences Reports Second Quarter 2025 Financial Results
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire

Performance

YTD
-47.5%
-47.5%
1 Month
+12.1%
+12.1%
3 Month
+43.3%
+43.3%
6 Month
+18.5%
+18.5%
1 Year
-68.8%
-68.8%

More News

Read More
Beyond the Headlines: A Look at Today's Key Corporate Earnings Reports
Via MarketMinute
Topics Economy Stocks
What to Expect from Maravai LifeSciences's Earnings
Via Benzinga
Earnings Scheduled For August 11, 2025
Via Benzinga
Maravai LifeSciences To Host Earnings Conference Call on Monday, August 11, 2025
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
MARAVAI LIFESCIENCES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Maravai LifeSciences Holdings, Inc. - MRVI
From Kahn Swick & Foti, LLC
Via Business Wire
MARAVAI INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Earnings Scheduled For May 12, 2025
Via Benzinga
MARAVAI ALERT: Bragar Eagel & Squire, P.C. is Investigating Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MARAVAI ALERT: Bragar Eagel & Squire, P.C. is Investigating Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MARAVAI LIFESCIENCES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Maravai LifeSciences Holdings, Inc. - MRVI
From Kahn Swick & Foti, LLC
Via Business Wire
Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Officer
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
Maravai ALERT: Bragar Eagel & Squire, P.C. is Investigating Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Insights Ahead: Maravai LifeSciences's Quarterly Earnings
Via Benzinga
Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
TriLink BioTechnologies® and Quantoom Biosciences Sign License and Supply Agreement for CleanCap® mRNA Capping Technology
From TriLink BioTechnologies
Via Business Wire
CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
Maravai LifeSciencesReleases 2024 Sustainability Report
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
TriLink BioTechnologies® debuts its first mRNA synthesis kit with CleanCap® capping technology; Celebrates launch with kit donations to top academic institutions
From TriLink BioTechnologies
Via Business Wire
TriLink BioTechnologies® and the International Vaccine Institute Sign a Memorandum of Understanding to Support the Development of mRNA-based Vaccines
From TriLink BioTechnologies
Via Business Wire
These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results
Via Benzinga
Assessing Maravai LifeSciences: Insights From 5 Financial Analysts
Via Benzinga
Maravai Lifesciences Reports First Quarter 2025 Financial Results
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
MRVI Investors Have Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire

Frequently Asked Questions

Is Maravai LifeSciences Holdings, Inc. - Class A common stock publicly traded?
Yes, Maravai LifeSciences Holdings, Inc. - Class A common stock is publicly traded.
What exchange does Maravai LifeSciences Holdings, Inc. - Class A common stock trade on?
Maravai LifeSciences Holdings, Inc. - Class A common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Maravai LifeSciences Holdings, Inc. - Class A common stock?
The ticker symbol for Maravai LifeSciences Holdings, Inc. - Class A common stock is MRVI on the Nasdaq Stock Market
What is the current price of Maravai LifeSciences Holdings, Inc. - Class A common stock?
The current price of Maravai LifeSciences Holdings, Inc. - Class A common stock is 2.880
When was Maravai LifeSciences Holdings, Inc. - Class A common stock last traded?
The last trade of Maravai LifeSciences Holdings, Inc. - Class A common stock was at 09/18/25 02:14 PM ET
What is the market capitalization of Maravai LifeSciences Holdings, Inc. - Class A common stock?
The market capitalization of Maravai LifeSciences Holdings, Inc. - Class A common stock is 323.37M
How many shares of Maravai LifeSciences Holdings, Inc. - Class A common stock are outstanding?
Maravai LifeSciences Holdings, Inc. - Class A common stock has 323M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.